Review of the Standard and Advanced Screening, Staging Systems and Treatment Modalities for Cervical Cancer
Open Access
Abstract
Cancer arising from the uterine cervix is the fourth most common cause of cancer death among women worldwide. Almost 90% of cervical cancer mortality has occurred in low- and middle-income countries. One of the major aetiologies contributing to cervical cancer is the persistent infection by the cancer-causing types of the human papillomavirus. The disease is preventable if the premalignant lesion is detected early and managed effectively. In this review, we outlined the standard guidelines that have been introduced and implemented worldwide for decades, including the cytology, the HPV detection and genotyping, and the immunostaining of surrogate markers. In addition, the staging system used to classify the premalignancy and malignancy of the uterine cervix, as well as the safety and efficacy of the various treatment modalities in clinical trials for cervical cancers, are also discussed. In this millennial world, the advancements in computer-aided technology, including robotic modules and artificial intelligence (AI), are also incorporated into the screening, diagnostic, and treatment platforms. These innovations reduce the dependence on specialists and technologists, as well as the work burden and time incurred for sample processing. However, concerns over the practicality of these advancements remain, due to the high cost, lack of flexibility, and the judgment of a trained professional that is currently not replaceable by a machine.Keywords
This publication has 186 references indexed in Scilit:
- HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trialJournal of Translational Medicine, 2013
- Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial dataBMJ, 2012
- Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancerRadiotherapy and Oncology, 2011
- Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registriesThe Lancet Oncology, 2011
- Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept TrialISRN Obstetrics and Gynecology, 2011
- A Phase II Trial of Erlotinib in Recurrent Squamous Cell Carcinoma of the CervixInternational Journal of Gynecological Cancer, 2009
- A Phase I Trial of a Human Papillomavirus DNA Vaccine for HPV16+ Cervical Intraepithelial Neoplasia 2/3Clinical Cancer Research, 2008
- A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural ChinaThe Lancet Oncology, 2008
- Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia IIIGynecologic Oncology, 2007
- Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancerThe Lancet, 1997